[
  {
    "id": "workflow_001",
    "name": "ROPAD Genetic Screening Referral",
    "description": "Processes genetic screening results from the ROPAD observational study to identify and refer mutation-positive candidates to the appropriate interventional trial team.",
    "modified": "2024-05-20",
    "approval": "Yes",
    "actions": [
      {
        "actionNumber": 1,
        "action": "Refer LRRK2+ Candidates for Parkinson's Trial",
        "input": "email",
        "output": "email",
        "description": "Parse incoming genetic report for LRRK2 mutation and forward positive results to the BIIB122/DNL151 study team for eligibility review."
      },
      {
        "actionNumber": 2,
        "action": "Log Negative/Other Results",
        "input": "email",
        "output": "CTMS",
        "description": "Log subjects with negative or other non-target mutations in the CTMS for the ROPAD observational study."
      }
    ]
  },
  {
    "id": "workflow_002",
    "name": "Partner SAE Forwarding (BIIB122/DNL151)",
    "description": "Automates the distribution of Serious Adverse Event reports for the BIIB122/DNL151 study to internal safety and the Biogen partner safety team as per the SDEA.",
    "modified": "2024-04-18",
    "approval": "No",
    "actions": [
      {
        "actionNumber": 1,
        "action": "Acknowledge Site Report",
        "input": "email",
        "output": "email",
        "description": "Send an automated confirmation to the reporting site acknowledging receipt of the SAE."
      },
      {
        "actionNumber": 2,
        "action": "Distribute SAE to Safety Teams",
        "input": "email",
        "output": "email",
        "description": "Forward the complete SAE report to Denali Pharmacovigilance and the designated Biogen Safety contact list."
      }
    ]
  }
]